Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

319 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Initial results of a Phase I dose-escalation trial of concurrent and maintenance erlotinib and reirradiation for recurrent and new primary head-and-neck cancer.
Rusthoven KE, Feigenberg SJ, Raben D, Kane M, Song JI, Nicolaou N, Mehra R, Burtness B, Ridge J, Swing R, Lango M, Cohen R, Jimeno A, Chen C. Rusthoven KE, et al. Among authors: jimeno a. Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):1020-5. doi: 10.1016/j.ijrobp.2009.09.003. Epub 2010 Mar 16. Int J Radiat Oncol Biol Phys. 2010. PMID: 20231078 Clinical Trial.
Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer.
Keysar SB, Le PN, Anderson RT, Morton JJ, Bowles DW, Paylor JJ, Vogler BW, Thorburn J, Fernandez P, Glogowska MJ, Takimoto SM, Sehrt DB, Gan GN, Eagles-Soukup JR, Serracino H, Hirsch FR, Lucia MS, Thorburn A, Song JI, Wang XJ, Jimeno A. Keysar SB, et al. Among authors: jimeno a. Cancer Res. 2013 Jun 1;73(11):3381-92. doi: 10.1158/0008-5472.CAN-12-4047. Epub 2013 Apr 10. Cancer Res. 2013. PMID: 23576557 Free PMC article.
A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins.
Keysar SB, Astling DP, Anderson RT, Vogler BW, Bowles DW, Morton JJ, Paylor JJ, Glogowska MJ, Le PN, Eagles-Soukup JR, Kako SL, Takimoto SM, Sehrt DB, Umpierrez A, Pittman MA, Macfadden SM, Helber RM, Peterson S, Hausman DF, Said S, Leem TH, Goddard JA, Arcaroli JJ, Messersmith WA, Robinson WA, Hirsch FR, Varella-Garcia M, Raben D, Wang XJ, Song JI, Tan AC, Jimeno A. Keysar SB, et al. Among authors: jimeno a. Mol Oncol. 2013 Aug;7(4):776-90. doi: 10.1016/j.molonc.2013.03.004. Epub 2013 Apr 4. Mol Oncol. 2013. PMID: 23607916 Free PMC article.
Epithelial stem cell mutations that promote squamous cell carcinoma metastasis.
White RA, Neiman JM, Reddi A, Han G, Birlea S, Mitra D, Dionne L, Fernandez P, Murao K, Bian L, Keysar SB, Goldstein NB, Song N, Bornstein S, Han Z, Lu X, Wisell J, Li F, Song J, Lu SL, Jimeno A, Roop DR, Wang XJ. White RA, et al. Among authors: jimeno a. J Clin Invest. 2013 Oct;123(10):4390-404. doi: 10.1172/JCI65856. Epub 2013 Sep 3. J Clin Invest. 2013. PMID: 23999427 Free PMC article.
A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.
Jimeno A, Shirai K, Choi M, Laskin J, Kochenderfer M, Spira A, Cline-Burkhardt V, Winquist E, Hausman D, Walker L, Cohen RB. Jimeno A, et al. Ann Oncol. 2015 Mar;26(3):556-61. doi: 10.1093/annonc/mdu574. Epub 2014 Dec 18. Ann Oncol. 2015. PMID: 25524478 Free article. Clinical Trial.
A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.
Jimeno A, Bauman JE, Weissman C, Adkins D, Schnadig I, Beauregard P, Bowles DW, Spira A, Levy B, Seetharamu N, Hausman D, Walker L, Rudin CM, Shirai K. Jimeno A, et al. Oral Oncol. 2015 Apr;51(4):383-8. doi: 10.1016/j.oraloncology.2014.12.013. Epub 2015 Jan 13. Oral Oncol. 2015. PMID: 25593016 Free PMC article. Clinical Trial.
319 results